Related Experiment Video
Updated: Jun 29, 2026

Assessment of Mitochondrial Functions and Cell Viability in Renal Cells Overexpressing Protein Kinase C Isozymes
Published on: January 7, 2013
Dual roles for coactivator activator and its counterbalancing isoform coactivator modulator in human kidney cell
Yun Kyoung Kang1, Rachel Schiff, Lan Ko
1Department of Molecular and Cellular Biology, Baylor College of Medicine, Houston, Texas 77030, USA.
Abstract:
Coactivator activator (CoAA) has been reported to be a coactivator that regulates steroid receptor-mediated transcription and alternative RNA splicing. Herein, we show that CoAA is a dual-function coregulator that inhibits G(1)-S transition in human kidney cells and suppresses anchorage-independent growth and xenograft tumor formation. Suppression occurs in part by down-regulating c-myc and its downstream effectors ccnd1 and skp2 and causing accumulation of p27/Kip1 protein. In this cellular setting, CoAA directly represses the proto-oncogene c-myc by recruiting HDAC3 protein and decreasing both the acetylation of histone H3 and the presence of RNA polymerase II on the c-myc promoter. Interestingly, a splicing isoform of CoAA, coactivator modulator (CoAM), antagonizes CoAA-induced G(1)-S transition and growth inhibition by negatively regulating the mRNA levels of the endogenous CoAA isoform. In addition, we found that expression of CoAA protein is significantly decreased in human renal cell carcinoma compared with normal kidney. Our study presents evidence that CoAA is a potential tumor suppressor in renal carcinoma and that CoAM is a counterbalancing splice isoform. This is, thus far, the only example of a nuclear receptor coregulator involved in suppression of kidney cancer and suggests potentially significant new roles for coregulators in renal cancer biology.
Insights
Coactivator activator (CoAA) acts as a tumor suppressor in kidney cancer by inhibiting cell growth and down-regulating the c-myc oncogene. A related isoform, CoAM, counterbalances this effect.
Area of Science:
- Molecular Biology
- Cancer Research
- Epigenetics
Background:
- Coactivator activator (CoAA) is known to regulate transcription and RNA splicing.
- Its role in cancer, particularly kidney cancer, is not well understood.
Purpose of the Study:
- To investigate the function of CoAA as a coregulator in human kidney cells.
- To determine CoAA's role in renal cell carcinoma (RCC).
Main Methods:
- Assessed CoAA's effect on cell cycle progression (G1-S transition) and anchorage-independent growth.
- Analyzed the regulation of c-myc, ccnd1, skp2, and p27/Kip1 protein levels.
- Investigated CoAA's mechanism of c-myc repression involving HDAC3, histone acetylation, and RNA polymerase II recruitment.
- Examined the function of the CoAA splicing isoform, coactivator modulator (CoAM).
- Compared CoAA protein expression in normal kidney tissue versus RCC.
Main Results:
- CoAA inhibits G1-S transition, anchorage-independent growth, and xenograft tumor formation.
- CoAA down-regulates c-myc, ccnd1, and skp2, leading to p27/Kip1 accumulation.
- CoAA represses c-myc by recruiting HDAC3, reducing histone H3 acetylation and RNA polymerase II at the c-myc promoter.
- The CoAM isoform antagonizes CoAA's inhibitory effects.
- CoAA protein expression is significantly decreased in human RCC compared to normal kidney tissue.
Conclusions:
- CoAA functions as a dual-role coregulator, inhibiting cell cycle progression and tumor growth.
- CoAA acts as a tumor suppressor in renal carcinoma by repressing the proto-oncogene c-myc.
- CoAM serves as a counterbalancing splice isoform.
- CoAA represents a novel nuclear receptor coregulator involved in kidney cancer suppression, highlighting potential new roles for coregulators in RCC biology.
Related Concept Videos
Co-activators and Co-repressors
Co-activators and Co-repressors
Eukaryotic Transcription Activators
The binding domains are capable of recognizing and interacting with regulatory sequences on the DNA. These domains are...
mTOR Signaling and Cancer Progression
The mTOR pathway or the...
mTOR Signaling and Cancer Progression
The mTOR pathway or the...
RNA Polymerase II Accessory Proteins
